Sirven N. (Liraes (EA 4470) Université Paris Descartes, Irdes), in collaboration with Rapp T.(Liraes (EA 4470) Université Paris Descartes)
Issues in Health Economics (Questions d'économie de la santé)
n° 216. 2016/03
Abstract and full text...
CONFERENCES & WORKSHOPS
3 QUESTIONS TO...
... Catherine Sermet, on the occasion of the publication of Issues in Health Economics (220), July-August 2016: "Disinvestment Strategies for Pharmaceuticals: An International Review of 5 countries".
1 / What is drug disinvestment and why studying this subject?
Over the past thirty years, pharmaceutical expenditure has steadily increased in most countries of the Organization for Economic Co-operation and Development (OECD). The need to finance new, often high-cost therapies leads governments to actively "disinvest" products with low therapeutic value, the cost of which was judged to be too high compared to the expected benefit...
CHART OF THE MONTH
Ambulatory care use rates to the nearest physician, according to level of Localized potential accessibility (LPA) [France, 2010]
Chart of the month: historic
December 9th, 2016